This discussion highlights the importance of pharmacist education of patients on immunotherapy, and barriers that may prevent patients from becoming active participants in the identification and management of irAEs.
SPEAKERS
Tonya Smith, PharmD, BCPS, is Clinical Pharmacy Specialist in Internal Medicine at Emory University Hospital Midtown in Atlanta, Georgia. Dr. Smith received her Pharm.D. degree from the Medical University of South Carolina in Charleston, South Carolina. She completed her PGY1 Pharmacy Practice Residency and PGY2 Internal Medicine Pharmacy Residency at University of Utah Health in Salt Lake City, Utah. Prior to Emory, Dr. Smith practiced on the inpatient medical oncology service and the Supportive Oncology & Survivorship Clinic at the Huntsman Cancer Institute in Salt Lake City, Utah.
Jordan McPherson, PharmD, MS, BCOP is Oncology Clinical Pharmacist in the ambulatory solid tumor clinics at the Huntsman Cancer Institute, an NCI designated cancer hospital, at the University of Utah Health and Adjunct Assistant Professor at the University of Utah College of Pharmacy in Salt Lake City, Utah. Dr. McPherson specializes in the treatment of skin cancer using immunotherapy and other targeted therapies. He serves as a Panelist on the NCCN Guidelines for Management of Immune Checkpoint Inhibitor-Related Toxicities, and is Past President of the Utah Society of Health-System Pharmacists. Dr. McPherson’s research efforts are well published in peer reviewed journals, including the Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, and Pharmacotherapy.
Relevant Financial Relationship Disclosures
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
As defined by the Standards of Integrity and Independence in Accredited Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
This podcast is provided by ASHP and supported by an independent medical education grant from Merck, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme. .